Drug firm BDR Pharma on Wednesday said it has inked a licensing pact with Eli Lilly and Company for the manufacturing and distribution of Baricitinib for the treatment of COVID-19 in India. The company said it has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company. Baricitinib has received restricted emergency use approval, for use in combination with Remdesivir, for treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults and pediatric patients two years of age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Eli Lilly has received the permission for the drug for restricted emergency use from Central Drugs Standard Control Organization, a division of the Ministry of Health.
The company has issued additional royalty-free, non-exclusive voluntary licences to Dr Reddy s, MSN Laboratories and Torrent Pharmaceuticals, who will be collaborating with Lilly to accelerate and expand the availability of Baricitinib in India, Eli Lilly and Company said in a statement.
New Delhi [India], May 13 (ANI): Eli Lilly and Company said on Thursday it has issued additional royalty-free, non-exclusive voluntary licenses to Dr Reddy's Ltd, MSN Laboratories and Torrent Pharmaceuticals who will collaborate to accelerate and expand the availability of baricitinib in India.
Eli Lilly and Company said on Thursday it has issued additional royalty-free, non-exclusive voluntary licenses to Dr Reddy s Ltd, MSN Laboratories and Torrent Pharmaceuticals who will collaborate to accelerate and expand the availability of baricitinib in India. These three additional voluntary licensing agreements will ensure high-quality manufacturing and accessibility of baricitinib, improving local treatment options available to positively impact the lives of people who are currently battling Covid-19 in India. Lilly received permission for restricted emergency use by the Central Drugs Standard Control Organisation (CDSCO) under Ministry of Health for baricitinib to be used in combination with remdesivir for treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Lilly inks three new pacts to expand availability of baricitinib drug
By IANS |
3 Views
US coronavirus death toll mounts to 6, Trump wants vaccine at âmaximum speedâ.. Image Source: IANS News
New Delhi, May 13 : Eli Lilly and Company on Thursday announced that it has issued additional royalty-free, non-exclusive voluntary licenses to the Indian pharmaceutical manufacturers of generic medicines, Dr. Reddy s Ltd, MSN Laboratories and Torrent Pharmaceuticals, who will be collaborating to accelerate and expand the availability of baricitinib for Covid treatment in India.
These three additional voluntary licensing agreements will ensure high quality manufacturing and accessibility of baricitinib during this pandemic improving the local treatment options available to positively impact the lives of people who are currently battling Covid in India.